Brief: Lee's Pharmaceutical Says Investigational NDA Of Staccato Fentanyl Accepted By NMPA
31/08/2020 16:06
Aug 31 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* UNIT'S INVESTIGATIONAL NEW DRUG APPLICATION OF STACCATO
FENTANYL
ACCEPTED BY NMPA
Source text for Eikon: urn:newsml:reuters.com:*:nHKS5DZC0B
Further company coverage: 0950.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals